Trial Profile
A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel; Topotecan
- Indications Carcinoma; Endometrial cancer; Ovarian cancer; Sarcoma
- Focus Therapeutic Use
- Acronyms ROCSAN
- 08 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2021 Trial design presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 29 Jul 2020 Status changed from not yet recruiting to recruiting.